Compare Abeona Therapeutics Inc (ABEO) vs GE Aerospace (GE) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs GE Aerospace — how do they compare? Abeona Therapeutics Inc trades at $6.71 (market cap $373.32M), while GE Aerospace trades at $356.8 (market cap $382.88B). The key difference: GE Aerospace is far larger — about 1025.6× Abeona Therapeutics Inc's market cap, and GE Aerospace pays a 0.51% dividend while Abeona Therapeutics Inc pays none. Which is the better fit depends on your goals.
| ABEO | GE | |
|---|---|---|
Market Cap | $373.32M | $382.88B |
Sector | Health | Industrials |
52-Week High | $7.23 | $378.68 |
52-Week Low | $4.17 | $247.05 |
Enterprise Value | $228.22M | $392.18B |
Dividend Yield | — | 0.51% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
GE trades at $378.68, up 0.31% today, with a bullish technical signal from moving averages and strong support at $375. The company reported three consecutive quarterly earnings beats, with Q1 2026 EPS of $1.86 exceeding expectations. Revenue grew to $45.86 billion in 2025, while net income margin improved to 17.86%. Recent news highlights robust order growth in aerospace and defense contracts, including a U.S. Air Force engine development deal announced May 19, 2026.
Outlook remains positive with a consensus price target of $394.33, though high valuation ratios (P/E 47.04) and rising debt levels pose risks. Aerospace demand and defense contracts support growth, but investors should monitor execution on expansion investments and macroeconomic pressures on aviation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About GE Aerospace
General Electric Company is a globally diversified technology and financial services company. The Company's products and services include aircraft engines, power generation, water processing, and household appliances to medical imaging, business and consumer financing, and industrial products.
Read more on GE →
